SB 239063 is a potent, selective, orally available p38 MAPK inhibitor with IC50 of 44 nM for both p38α and p38β.
SB 239063 shows no activity (>100 μM) against the γ- and δ-kinase isoforms, and a panel of protein kinase.
SB 239063 inhibits IL-1 and TNF-alpha production in LPS-stimulated human PBMCs (IC50= 0.12 and 0.35 uM).
SB 239063 reduces inflammatory cytokine production, airways eosinophil infiltration and persistence in vivo.
